COVID-19 – support of AdaptVac research

In mid-March, soon after the World Health Organization declared the COVID-19 pandemic, biotech company AdaptVac and researchers at University of Copenhagen, received an EU grant of EUR 2.7 million for their new COVID-19 vaccine development program. This was rapidly followed by a EUR 3 million Semper Ardens grant from the Carlsberg Foundation, given to Professor Ali Salanti at the University of Copenhagen, co-founder of AdaptVac.

Though new in the field of COVID-19 vaccine development, Dr. Salanti and his team have a solid virus-like particle (VLP) based vaccine platform.